All Posts

Highlight of Liso-cel
Liso-cel Shines in TRANSCEND FL: Impressive Complete Responses, Durable Overall Responses, and Manageable Safety as a Second-Line Treatment for Relapsed Follicular Lymphoma

Date of Abstract presentation10th December 2023IndicationsFollicular Lymphoma (FL)Abstract Number602Abstract typeOral In the TRANSCEND FL study, 130 individuals grappling with relapsed or refractory follicular lymphoma (FL) were actively involved and subjected to BREYANZI treatment within the second-line and thi...

Find More

jaypirca-for-chronic-lymphocytic-leukemia
Eli’s Jaypirca: A Beacon of Success in the BTK Inhibitor Market

As the battle intensifies among AbbVie, Johnson & Johnson, AstraZeneca, and BeiGene in the BTK inhibitor market, Eli Lilly stands out by forging a new direction in the landscape of blood cancer drugs. Just at the beginning of this month, the FDA granted accelerated approval to Lilly’s Jaypirca. This approval is...

Find More

unlocking-the-future-of-hematology-ash-2023-preview
Unlocking the Future of Hematology: A Sneak Peek into ASH 2023 Discoveries!

The upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition 2023 is just around the corner, and leading pharmaceutical giants like BMS, Genmab, AstraZeneca, Regeneron, BeiGene, ADC Therapeutics, Eli Lilly and Company, Janssen, and others are gearing up for this conference. This conference w...

Find More

MedTech News for Laminar, BD, Vivos, Zilia, Penumbra
Johnson & Johnson Medtech Acquired Laminar; BD Launched Advanced Vascular Access Ultrasound System; FDA Cleared Oral Device for Severe Sleep Apnea; FDA Clearanced the Zilia OcularTM FC Retinal Camera; First Patient Enrolled in Penumbra Study of Computer-assisted Vacuum Thrombectomy; US FDA Granted the BiVACOR Total Artificial Heart IDE Approval for First-in-Human Early Feasibility Study

FDA Cleared Oral Device for Severe Sleep Apnea From Vivos Therapeutics On November 29, 2023, Vivos Therapeutics announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Vivos’s removable CARE (Complete Airway Repositioning and Expansion) oral appliances developed for treat...

Find More

ixchiq-first-ever-chikungunya-vaccine
Valneva’s Ixchiq: First-Ever Chikungunya Vaccine

Over the past 15 years, an estimated 5 million cases of chikungunya have surfaced globally. This virus poses an escalating menace, having affected over half of the world’s nations. Recent cases in Spain, Italy, and France underscore its widespread reach. Additionally, the virus has expanded to new geographical area...

Find More

Implantable Drug Delivery Devices Market Outlook
Assessing the Emerging Trends in the Evolving Implantable Drug Delivery Device Landscape

The Implantable Drug Delivery Device market has experienced a monumental surge driven by an amalgamation of technological innovation, burgeoning demand, and the strategic maneuvers of key industry players. According to DelveInsight's latest assessment, the global Implantable Drug Delivery Device Market is poised to...

Find More

Pharma News for Merck, Roche, AbbVie, Abbisko Pfizer
FDA Grants Priority Review to Merck’s Application for KEYTRUDA Plus Padcev; Roche and Carmot Therapeutics’s Definitive Merger Agreement; AbbVie to Acquire ImmunoGen; FDA Grants Orphan Drug Designation to LP-284; Merck Announces Commercialization Agreement With Abbisko; Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial

FDA Grants Priority Review to Merck’s Application for KEYTRUDA Plus Padcev for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Merck, operating as MSD internationally, reported that the U.S. Food and Drug Administration (FDA) has prioritized the review of a supplementar...

Find More

dermatomyositis-treatment
Unraveling the Complexities of Dermatomyositis Treatment: A Comprehensive Review and Future Perspectives

Dermatomyositis, characterized by muscle weakness and skin symptoms, is a condition linked to increased morbidity and mortality. It markedly affects the quality of life for individuals afflicted, as well as the well-being of their families. According to DelveInsight estimates in the latest Dermatomyositis Epidemiol...

Find More

stelara-biosimilar-wezlana
Could Amgen’s Biosimilar Wezlana Pose a Challenge to Johnson & Johnson’s Stelara

The FDA recently approved Amgen’s Wezlana (ustekinumab-auub) for various inflammatory conditions, marking the first biosimilar approval referencing the popular J&J drug Stelara (ustekinumab). Wezlana, mirroring its reference product, is approved for treating multiple inflammatory diseases in adults, including m...

Find More

MedTech News for BrainSpec, Revvity, FormaPath, Pramand
Baird Medical’s Microwave Ablation System; BrainSpec’s AI-Backed Solution for Non-Invasive Brain Chemistry Measurement; AWAK’s AI-Enabled Kidney Disease Prediction Tool; Revvity’s EONIS Q System; FormaPath Announced Advancement in Cancer Pathology; Pramand Launched CraniSeal Dural Sealant

Baird Medical Received the US FDA Clearance for a Microwave Ablation System On November 22, 2023, Baird Medical announced the US Food and Drug Administration clearance of the company’s microwave ablation (MWA) system and disposable needles for use in the US. The clearance allows the use of the technology to a...

Find More